Amphastar Pharmaceuticals Free Cash Flow 2012-2026 | AMPH
Amphastar Pharmaceuticals free cash flow from 2012 to 2026. Free cash flow can be defined as a measure of financial performance calculated as operating cash flow minus capital expenditures.
| Amphastar Pharmaceuticals Annual Free Cash Flow | |
|---|---|
| 2025 | |
| 2024 | 172.35 |
| 2023 | 145.34 |
| 2022 | 65.57 |
| 2021 | 70.54 |
| 2020 | 23.41 |
| 2019 | 0.21 |
| 2018 | -8.37 |
| 2017 | 4.11 |
| 2016 | 17.18 |
| 2015 | -5.32 |
| 2014 | 0.55 |
| 2013 | 12.74 |
| 2012 | -25.31 |
| 2011 | 8.42 |
| Amphastar Pharmaceuticals Quarterly Free Cash Flow | |
|---|---|
| 2026-03-31 | |
| 2025-12-31 | |
| 2025-09-30 | 96.64 |
| 2025-06-30 | 49.41 |
| 2025-03-31 | 24.38 |
| 2024-12-31 | 172.35 |
| 2024-09-30 | 155.73 |
| 2024-06-30 | 109.56 |
| 2024-03-31 | 46.50 |
| 2023-12-31 | 145.34 |
| 2023-09-30 | 130.92 |
| 2023-06-30 | 76.77 |
| 2023-03-31 | 30.91 |
| 2022-12-31 | 65.57 |
| 2022-09-30 | 56.65 |
| 2022-06-30 | 41.90 |
| 2022-03-31 | 44.63 |
| 2021-12-31 | 70.54 |
| 2021-09-30 | 36.98 |
| 2021-06-30 | 41.63 |
| 2021-03-31 | 15.21 |
| 2020-12-31 | 23.41 |
| 2020-09-30 | 15.85 |
| 2020-06-30 | 12.11 |
| 2020-03-31 | -6.74 |
| 2019-12-31 | 0.21 |
| 2019-09-30 | 2.97 |
| 2019-06-30 | 23.65 |
| 2019-03-31 | -18.35 |
| 2018-12-31 | -8.37 |
| 2018-09-30 | -8.55 |
| 2018-06-30 | -11.70 |
| 2018-03-31 | -3.98 |
| 2017-12-31 | 4.11 |
| 2017-09-30 | 4.46 |
| 2017-06-30 | 13.40 |
| 2017-03-31 | 15.13 |
| 2016-12-31 | 17.18 |
| 2016-09-30 | 8.51 |
| 2016-06-30 | 10.70 |
| 2016-03-31 | 9.98 |
| 2015-12-31 | -5.32 |
| 2015-09-30 | -4.48 |
| 2015-06-30 | -3.74 |
| 2015-03-31 | -2.84 |
| 2014-12-31 | 0.55 |
| 2014-09-30 | -2.94 |
| 2014-06-30 | -12.36 |
| 2014-03-31 | -10.06 |
| 2013-12-31 | 12.74 |
| 2013-09-30 | 8.13 |
| 2013-06-30 | 11.95 |
| 2013-03-31 | -4.92 |
| 2012-12-31 | -25.31 |
| 2012-09-30 | |
| 2012-06-30 | |
| 2012-03-31 | |
| 2011-12-31 | |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical - Generic Drugs | $0.924B | $0.720B |
| Amphastar Pharmaceuticals, Inc. is a specialty pharmaceutical company. It focuses primarily on developing, manufacturing, marketing, and selling generic and proprietary injectable and inhalation products. The company products include Enoxaparin Sodium Injection; Amphadase; Cortrosyn for Injection; and prefilled disposable emergency syringes for crash cart use. Amphastar Pharmaceuticals, Inc. is headquartered in Rancho Cucamonga, California. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Teva Pharmaceutical Industries (TEVA) | Israel | $35.437B | 10.97 |
| BridgeBio Pharma (BBIO) | United States | $14.460B | 0.00 |
| Dr Reddy's Laboratories (RDY) | India | $11.109B | 17.29 |
| Aspen Pharmacare (APNHY) | South Africa | $3.708B | 0.00 |
| Supernus Pharmaceuticals (SUPN) | United States | $2.918B | 22.33 |
| Bausch Health Cos (BHC) | Canada | $2.086B | 1.50 |
| Taysha Gene Therapies (TSHA) | United States | $1.290B | 0.00 |
| Personalis (PSNL) | United States | $0.630B | 0.00 |
| Assembly Biosciences (ASMB) | United States | $0.451B | 0.00 |
| Sol-Gel Technologies (SLGL) | Israel | $0.210B | 0.00 |
| Metagenomi Therapeutics (MGX) | United States | $0.052B | 0.00 |
| Evoke Pharma (EVOK) | United States | $0.019B | 0.00 |
| Teligent (TLGT) | United States | $0.000B | 0.00 |